RCM
SABS icon

RA Capital Management’s SAB Biotherapeutics SABS Stock Holding History

RA Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.9M Hold
4,401,500
– – 0.18% 63
2025
Q4 		$16.5M Hold
4,401,500
– – 0.17% 53
2025
Q3 		$8.85M Buy
+4,401,500
New +$9.95M 0.11% 53
2024
Q1 		– Sell
-237,408
Closed -$1.63M – 78
2023
Q4 		$1.63M Buy
+237,408
New +$1.99M 0.03% 61

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SSC
Spruce Street Capital New York $416M AUM

RA Capital Management's SABS Position: Q1 2026 in Review

RA Capital Management held its SAB Biotherapeutics (SABS) position steady in Q1 2026 at 4,401,500 shares worth $16.9M. The position accounts for 0.18% of the portfolio, ranked #63.

RA Capital Management first reported a position in SABS in Q4 2023 and has held it in 4 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • RA Capital Management held 4,401,500 shares of SAB Biotherapeutics worth $16.9M as of Q1 2026.
  • RA Capital Management left its SAB Biotherapeutics share count unchanged in Q1 2026.
  • SAB Biotherapeutics made up 0.18% of RA Capital Management's portfolio in Q1 2026, its #63 holding.
  • RA Capital Management first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 4 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.